Stem cell and regenerative medicine basics
Stem-cell therapies are not one treatment.
The useful question is always specific: which cell or biologic product, from which source, for which disease, delivered how, under what regulatory controls, and supported by what clinical evidence?
Autologous vs allogeneic
The first distinction is whether the material comes from the patient or from a donor.
Autologous
Cells or blood-derived products come from the same patient. This may reduce immune mismatch, but quality can vary with age, illness, medications, and processing method.
Allogeneic
Cells come from a donor or cell bank. This can support standardized manufacturing, but raises questions about immune response, donor screening, potency, storage, and regulation.
Minimally manipulated vs manufactured
A same-day preparation is very different from a cultured, expanded, engineered, or cryopreserved cell product. The regulatory and safety issues change accordingly.
Major stem-cell categories
Different stem cells behave differently. Evidence for one category should not be casually transferred to another.
HSCs
Hematopoietic stem cells rebuild blood and immune systems. They are central to bone marrow, peripheral blood, and cord blood transplantation, especially in hematology.
MSCs
Mesenchymal stromal/stem cells are studied for immune modulation, trophic signaling, extracellular vesicles, and tissue repair. Clinical results vary by source, donor, culture conditions, dose, and indication.
Tissue-specific cells
Some products use specialized progenitors or tissue-derived cells, for example cartilage, skin, corneal, islet, or retinal approaches. These are usually indication-specific.
Engineered or reprogrammed cells
Gene-modified cells, iPSC-derived cells, and encapsulated cell products can be powerful but require high manufacturing and safety scrutiny.
Common harvesting sources
The source of the cells influences yield, composition, handling, and evidence.
Bone marrow
Bone marrow aspirate can provide hematopoietic and stromal cell populations. It is used in established transplant medicine and studied in orthopedics, cardiology, and other repair settings.
Adipose tissue
Fat-derived stromal vascular fraction or cultured adipose-derived cells are studied for orthopedic, wound, fistula, urologic, and cosmetic indications. Processing methods vary widely.
Umbilical cord and cord blood
Cord blood is an established HSC source in transplantation. Umbilical cord tissue and Wharton jelly MSC products are widely studied, usually as donor-derived products.
Peripheral blood
Mobilized peripheral blood stem cells are a major HSC transplant source. This is distinct from platelet concentrates such as PRP or PRF.
Regenerative medicine beyond stem cells
Not every regenerative therapy is a stem-cell therapy. Many approaches use blood products, scaffolds, signals, or tissue engineering.
PRP
Platelet-rich plasma concentrates platelets and growth-factor signaling from blood. Evidence is most developed in selected musculoskeletal and wound indications, but preparation protocols differ.
PRF
Platelet-rich fibrin forms a fibrin matrix that can hold platelets, leukocytes, and signaling molecules. It is common in dentistry, oral surgery, wound care, and tissue repair research.
Exosomes and extracellular vesicles
Cell-derived vesicles may carry proteins, lipids, and RNA signals. They are biologically interesting but still need stronger standardization, potency testing, and clinical evidence.
Scaffolds, biomaterials, and tissue engineering
Collagen matrices, hydrogels, 3D bioprinting, decellularized tissues, and engineered constructs aim to guide repair, sometimes with cells and sometimes without them.
Repository overview
The Dr Stemcells repository is the evidence map behind these summaries: a living table of papers, trial records, PDFs, and approval-readiness judgments organized by organ system.
PubMed evidence table
883 abstract-linked records are organized by organ system, outcome direction, confidence, PMID, journal, and research context.
Clinical trial landscape
53 ClinicalTrials.gov records are summarized by NCT number, organ system, phase, recruitment status, and approval-proximity.
Local PDF library
Downloaded open-access PDFs are filed by organ system so full-text review can sit beside the abstract-level evidence map.
Approval-readiness view
The repository separates approved or regulated uses from near-clinical applications, promising but immature fields, and areas that clearly need more work.
How to read the repository
The repository is designed for orientation, not hype. It is a triage tool for asking better questions before making clinical claims.
Positive is not proof
A positive abstract or early trial signal still needs full-text review, endpoints, durability, safety, and bias assessment.
One indication is not another
Evidence for hematology, cartilage, wounds, diabetes, neurology, or orthopedics should not be generalized across diseases.
Manufacturing matters
Cell source, donor type, manipulation, culture, dose, route, storage, and release testing can change the meaning of a study.
Open the full repository
Use the searchable repository to compare organ systems, follow trials, inspect outcomes, and identify what is approaching approval versus what remains experimental.
Continue exploring
Use the repository to compare research by organ system, evidence type, outcome direction, and clinical maturity. For a gentler introduction, start with the patient guide.